Teripalimab
WebThe PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor that has shown clinical efficacy in advanced esophageal cancer, but there has been relatively few data on neoadjuvant therapy. This study was designed to comprehend the pathological complete response rate, disease-free survival, and safety of neoadjuvant therapy with ... Web[email protected] 28 Argonaut, Suite 150 Aliso Viejo, CA 92656 Phone: (+1) 949-248-RARE (7273)
Teripalimab
Did you know?
WebTeripalimab. Status: Unknown status. Location: See location... Intervention Type: Drug. Study Type: Interventional. Study Phase: Phase 2. Summary. This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell … WebSimmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab. Drug: Simmtecan, 5-FU and l-LV. Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
WebJun 19, 2024 · Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma. This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of Simmtecan and the 5-FU/LV regimen (FOLFSIM regimen) plus Toripalimab. ... WebFeb 15, 2024 · Purpose This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined …
WebThe PD-1 antibody, teripalimab, is an immunological checkpoint inhibitor that has shown clinical efficacy in advanced esophageal cancer, but there has been relatively few data … WebNov 26, 2024 · Drug: Teripalimab; Phase 2: Detailed Description. Esophageal cancer ranks the eighth most common cancer in Worldwide. And the third among men and the fifth …
WebThe study was an open-label, single-arm, phase II trial. Unresectable, locally advanced or metastatic ICC patients (pts) were given 240 mg toripalimab Q3W via intravenous (IV) …
WebTeripalimab; Study Participants. 44; Brief Summary This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent Chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And this study will provide valuable information for further clinical trials of preoperative ... hintokuWebDisease Ontology: 11 A carcinoma that derives from neuroendocrine cells.. MalaCards based summary: Neuroendocrine Carcinoma, also known as carcinoma, neuroendocrine, is related to cervical large cell neuroendocrine carcinoma and lung combined large cell neuroendocrine carcinoma.An important gene associated with Neuroendocrine … hinton2001WebJun 19, 2024 · Experimental: FOLFSIM Plus Teripalimab. Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab; Active Comparator: EP/EC. Etoposide plus Cisplatin or Carboplatin; Clinical Trial Outcome Measures Primary Measures. Overall survival. Time Frame: 2 years; Measure of time from study treatment to patient’s death or … hintojen vertailuWebThe prognosis of locally advanced esophageal squamous cell carcinoma is poor,the role of chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been … hinton2006论文WebRegistry name: “Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer”. Keywords: Esophageal cancer; neoadjuvant immunochemotherapy; clinical trial; phase II … hintoki pressWebPhase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma : Secondary IDs: Study Status. Record Verification: June 2024 : Overall Status: Recruiting: Study Start: June 19, 2024 : Primary Completion: hinton2001 enjinWebPhase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma. INTRODUCTION. Org … hinton1986